Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.